BioGaia ABBGLAF 100 EV-to-EBITDA is 23.15 as of Jul. 13, 2026, which is 5% below its 10-year median of 24.31. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.55 (Fairly Valued). The stock has 2 warning signs investors should review. Among 739 Drug Manufacturers companies, BioGaia AB ranks worse than 73.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioGaia AB's enterprise value is $1,119.6 Mil.
BioGaia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $48.4 Mil. Therefore, BioGaia AB's EV-to-EBITDA for today is 23.15.
The historical rank and industry rank for BioGaia AB's EV-to-EBITDA or its related term are showing as below:
BGLAF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.49 Med: 24.31 Max: 38.57
Current: 24.05
During the past 13 years, the highest EV-to-EBITDA of BioGaia AB was 38.57. The lowest was 14.49. And the median was 24.31.
BGLAF's EV-to-EBITDA is ranked worse than 73.88% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.99
vs BGLAF: 24.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
BioGaia AB (OTCPK:BGLAF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioGaia AB's share price for today is $12.20.
BioGaia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.349.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for BioGaia AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioGaia AB's EV-to-EBITDA falls into.
BioGaia AB's current Enterprise Value is $1,119.6 Mil.
BioGaia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a EV-to-EBITDA of 23.15 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioGaia AB. This is near median its historical median of 24.31. Over the past decade, BioGaia AB's EV-to-EBITDA has ranged from 14.49 to 38.57. According to the industry distribution chart, BioGaia AB ranks #546 out of 739 companies in the Drug Manufacturers industry, placing it in the top 73.9%.
Is BioGaia AB's EV-to-EBITDA too high?
BioGaia AB's current EV-to-EBITDA of 23.15 is near median its 10-year median of 24.31. Over the past 10 years, this metric has ranged from a low of 14.49 to a high of 38.57. The Drug Manufacturers industry median EV-to-EBITDA is 12.99. BioGaia AB's value of 23.15 is 78.2% above this industry median. Based on the distribution chart, BioGaia AB ranks #546 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #546 out of 739 companies for EV-to-EBITDA. This places BioGaia AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.99. BioGaia AB's value of 23.15 is 78.2% above this benchmark. Historically, BioGaia AB's own EV-to-EBITDA has ranged from 14.49 to 38.57 over the past decade. While the company's 10-year median is 24.31 vs. the industry median of 12.99, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.99, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current EV-to-EBITDA of 23.15 is 78.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on BioGaia AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current EV-to-EBITDA is 23.15, which is near median its own 10-year median of 24.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.55, compared to a current price of $12.20 — trading 2.8% below its estimated fair value. The current EV-to-EBITDA is 23.15, which is near median its 10-year median of 24.31 and 78.2% above the Drug Manufacturers industry median of 12.99. BioGaia AB's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current EV-to-EBITDA is 23.15 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.8% below its estimated GF Value™ of $12.55.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
EV-to-EBITDA: 23.15 (near median its 10-year median of 24.31)
GF Value™: $12.55 vs. price of $12.20 (2.8% below fair value)
Industry Position: 78.2% above the Drug Manufacturers median (#546 of 739)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
